[go: up one dir, main page]

CO2022002567A2 - Proteínas de fusión terapéuticas - Google Patents

Proteínas de fusión terapéuticas

Info

Publication number
CO2022002567A2
CO2022002567A2 CONC2022/0002567A CO2022002567A CO2022002567A2 CO 2022002567 A2 CO2022002567 A2 CO 2022002567A2 CO 2022002567 A CO2022002567 A CO 2022002567A CO 2022002567 A2 CO2022002567 A2 CO 2022002567A2
Authority
CO
Colombia
Prior art keywords
acute
fusion proteins
chronic
therapeutic fusion
injuries
Prior art date
Application number
CONC2022/0002567A
Other languages
English (en)
Inventor
Sebastien Irigaray
Laurent Klein
Darko Skegro
Marco Villani
Karl Welzenbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022002567(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2022002567A2 publication Critical patent/CO2022002567A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)

Abstract

La presente invención se refiere a proteínas de fusión adecuadas para su uso como medicamento o herramienta de investigación. Los usos terapéuticos de las proteínas de fusión pueden incluir la prevención o el tratamiento de trastornos inflamatorios agudos o crónicos y microvasculares y de órganos impulsados por el sistema inmunitario, por ejemplo, lesión renal aguda, infarto agudo de miocardio, dificultad respiratoria aguda o enfermedad pulmonar obstructiva crónica, fibrosis y otras lesiones de órganos resultantes de traumatismos de tejidos y lesiones agudas y crónicas.
CONC2022/0002567A 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas CO2022002567A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06
PCT/IB2020/058251 WO2021044361A1 (en) 2019-09-06 2020-09-04 Therapeutic fusion proteins

Publications (1)

Publication Number Publication Date
CO2022002567A2 true CO2022002567A2 (es) 2022-04-08

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
CONC2022/0002567A CO2022002567A2 (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas
CONC2022/0002545A CO2022002545A2 (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
CONC2022/0002545A CO2022002545A2 (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas

Country Status (21)

Country Link
US (3) US20230265160A1 (es)
EP (3) EP4025238A1 (es)
JP (3) JP2022547050A (es)
KR (3) KR20220058585A (es)
CN (8) CN114341194A (es)
AR (2) AR119905A1 (es)
AU (3) AU2020343926B2 (es)
BR (2) BR112022003745A2 (es)
CA (3) CA3152990A1 (es)
CO (2) CO2022002567A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220016A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220055A1 (es)
MX (2) MX2022002637A (es)
PE (2) PE20221051A1 (es)
PH (2) PH12022550538A1 (es)
TW (1) TW202122414A (es)
WO (3) WO2021044360A1 (es)
ZA (2) ZA202201827B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
WO2022225796A1 (en) * 2021-04-22 2022-10-27 BioLegend, Inc. Phosphatidylserine binding agents for the detection and depletion of phosphatidylserine positive cells
KR20230001168A (ko) 2021-06-28 2023-01-04 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
CN119158000A (zh) * 2023-10-25 2024-12-20 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CN101203234B (zh) 2005-05-13 2012-10-10 范斯坦医药研究院 乳脂小球表皮生长因子-因子ⅷ和脓毒病
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CN101910411B (zh) 2007-11-15 2015-04-29 范斯坦医药研究院 使用mfg-e8预防和治疗缺血/再灌注后的炎症和器官损伤
JP2013509170A (ja) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ アルブミン変異体
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
CN102939304B (zh) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 白蛋白衍生物和变体
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
WO2012112188A1 (en) 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
WO2012149254A2 (en) 2011-04-28 2012-11-01 The Feinstein Institute For Medical Research Mfg-e8 and uses thereof
AU2012251583B2 (en) 2011-05-05 2017-06-08 Albumedix Ltd. Albumin variants
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
AU2013343503B2 (en) 2012-11-08 2017-12-14 Albumedix Ltd. Albumin variants
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
EP3037534B1 (en) 2013-08-23 2021-02-17 Riken Polypeptide exhibiting fluorescent properties, and utilization of same
WO2015150757A1 (en) * 2014-03-31 2015-10-08 British Telecommunications Public Limited Company Data communication
DK3127923T3 (da) * 2014-03-31 2021-11-22 Hanmi Pharm Ind Co Ltd Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding
US20170136089A1 (en) * 2014-05-15 2017-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CN118063619A (zh) * 2017-03-02 2024-05-24 诺华股份有限公司 工程化的异源二聚体蛋白质
US11028139B2 (en) 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
JP7659499B2 (ja) 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法

Also Published As

Publication number Publication date
JOP20220058A1 (ar) 2023-01-30
WO2021044361A1 (en) 2021-03-11
TW202122415A (zh) 2021-06-16
IL290675A (en) 2022-04-01
EP4025238A1 (en) 2022-07-13
CO2022002545A2 (es) 2022-04-08
CN118812727A (zh) 2024-10-22
PH12022550539A1 (en) 2023-03-20
ECSP22016558A (es) 2022-04-29
CN114341194A (zh) 2022-04-12
CR20220096A (es) 2022-05-11
KR20220058588A (ko) 2022-05-09
CA3152990A1 (en) 2021-03-11
CN118909136A (zh) 2024-11-08
CU20220015A7 (es) 2022-10-11
WO2021044360A1 (en) 2021-03-11
AU2020340618A1 (en) 2022-04-07
PE20221051A1 (es) 2022-06-30
JOP20220055A1 (ar) 2023-01-30
US20230220048A1 (en) 2023-07-13
CU20220016A7 (es) 2022-10-11
MX2022002638A (es) 2022-03-25
TW202122414A (zh) 2021-06-16
WO2021044362A1 (en) 2021-03-11
ZA202201827B (en) 2023-11-29
IL290618A (en) 2022-04-01
JP2022547111A (ja) 2022-11-10
CN114341195A (zh) 2022-04-12
CN118667031A (zh) 2024-09-20
IL290660A (en) 2022-04-01
CN119285791A (zh) 2025-01-10
AU2020343926B2 (en) 2024-11-21
AR119902A1 (es) 2022-01-19
ZA202201828B (en) 2023-10-25
US20230308835A1 (en) 2023-09-28
ECSP22016180A (es) 2022-04-29
EP4025237A1 (en) 2022-07-13
KR20220058586A (ko) 2022-05-09
JP2022547051A (ja) 2022-11-10
CN118772293A (zh) 2024-10-15
CA3152500A1 (en) 2021-03-11
AU2020343926A1 (en) 2022-04-07
AU2020343512A1 (en) 2022-04-07
BR112022003745A2 (pt) 2022-05-31
JP2022547050A (ja) 2022-11-10
KR20220058585A (ko) 2022-05-09
EP4025239A1 (en) 2022-07-13
US20230265160A1 (en) 2023-08-24
AU2020340618B2 (en) 2025-01-23
BR112022003762A2 (pt) 2022-05-31
PE20220401A1 (es) 2022-03-22
AR119905A1 (es) 2022-01-19
CR20220089A (es) 2022-03-30
MX2022002637A (es) 2022-03-25
CN114302896A (zh) 2022-04-08
CA3152499A1 (en) 2021-03-11
PH12022550538A1 (en) 2023-03-20

Similar Documents

Publication Publication Date Title
ECSP22016558A (es) Proteínas de fusión terapéuticas
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
DOP2017000104A (es) Cromanos sustituidos y métodos para su uso
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EP3784213C0 (en) SUSTAINED-RELEASE INHALABLE LIPOSOMAL COMPOSITION FOR THE TREATMENT OF PULMONARY DISEASES
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
MX2017000448A (es) Uso terapeutico de proteinas morfogeneticas oseas.
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
RU2017124487A (ru) НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
BRPI0516626A (pt) pteridinas substituìdas e uso das mesmas
BRPI0516810A (pt) uso de conjugados de lipìdios no tratamento de doenças
ECSP16078100A (es) Nuevo uso de n,n -2-bis- mercaptoetil isoftalamida
AR062582A1 (es) Variedades polimorficas de derivados de 1-azonia-biciclo-[2.2.2]-octano
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин